Release Date: September 30, 2025

Expiration Date: September 30, 2026

Activity Overview

While treatment options for advanced non–small cell lung cancer (NSCLC) have expanded, challenges remain in overcoming resistance and optimizing outcomes across diverse patient populations. Novel therapies, such as bispecific antibodies and antibody-drug conjugates (ADCs), offer promising new mechanisms and are reshaping the future of care.

This certified CME satellite symposium, held in conjunction with the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, features expert-led presentations and interactive discussions on emerging clinical trial data, real-world applications, and future directions for bispecifics and ADCs. Attendees will gain practical guidance on integrating these agents into personalized treatment strategies for advanced NSCLC.

This educational activity is an archive of the live virtual symposium held on September 6, 2025.

Target Audience

This educational activity is directed toward physicians, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the diagnosis and treatment of NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Integrate the latest evidence and disease-/patient-specific characteristics into personalized treatment plans for advanced NSCLC
Describe the unique mechanisms of emerging bispecific antibodies and ADCs being investigated for the treatment of advanced NSCLC
Assess the implications of recent clinical trial evidence on the potential roles for emerging bispecific antibodies and ADCs in advanced NSCLC

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Summit Therapeutics, Inc.

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

GET STARTED WITH THIS PROGRAM:

Related Content